Cytomegalovirus Infection Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Cytomegalovirus Infection Treatment Market Size, Share & Trends Analysis Report By Drug Type, By Application, By Infection, By Diagnosis Test, By Route of Administration, By Distribution Channel, By End-user, By Region, And Segment Forecasts, 2024 – 2031

Report Overview

The Global Cytomegalovirus Infection Treatment Market reached US$ 516.36 million in 2023 and is expected to reach US$ 858.65 million by 2031, growing at a CAGR of 6.7% during the forecast period 2024-2031.

CMV (Cytomegalovirus) can cause infections which may lead to severe complications in immunosuppressed people like Pediatrics, Organ transplant recipients and HIV/AIDS patients. There is a day-by-day shoot-up in prevalence of CMV retinitis and congenital CMV infections which further led to the initiation of public awareness programs by the governments to prevent and manage the disease. 

As a result of this, there is a surge in medications such as Antiviral therapies, Stem cell transplantation, and Vaccination. Among these treatments, antiviral therapy emerged as the main treatment for the infection for a large section of the population but due to the risks involved with that there is a need for better treatments that the pharmacy and utical industry is looking for.

Market Scope

For more details on this report - Request for Sample

Market Dynamics: Drivers

Increasing Prevalence of Viral Infections

The demand for the cytomegalovirus infection treatment market is driven by multiple factors. The rising prevalence of viral infections such as HIV/AIDS propels the market growth. Moreover, the global objective of reaching 95% HIV patient diagnosis and treatment rates by 2025 will support market expansion. 

Furthermore, the demand for treatment will be fueled by the growing seroprevalence of CMV infection with age among people older than six, as well as the increasing prevalence of the infection. For instance, according to the National Library of Medicine article published in August 2023, around 59% of individuals above six years old have encountered CMV, and seroprevalence rises with age.

 CMV infection can be personified as a primary infection, reinfection, or reactivation, occurring through various modes such as blood products, breastfeeding, close-contact settings, perinatal transmission, and sexual transmission.

 Reactivation, particularly in immunocompromised patients, is linked to increased morbidity and mortality. According to the National Library of Medicine article published in August 2023, for individuals with intact immunity, CMV rarely contributes to mortality. Moreover, CMV infects approximately 60% to 70% of adults in industrialized countries and nearly 100% in emerging countries.

 CMV imposes a burden on T-cell antigenic surveillance and contributes to immune dysfunction. Additionally, congenital CMV stands as a primary infectious cause of conditions such as learning disabilities, deafness, and intellectual disability. It serves as a significant driver for the CMV treatment market.

Restraints

Factors such as adverse effects and risks related to cytomegalovirus drugs, high cost associated with the treatment, lack of healthcare infrastructure, lack of awareness among people, shortage of skilled professionals, and stringent regulatory requirements for the approval of new treatments are expected to hamper the market.

Segment Analysis

The cytomegalovirus infection treatment market is segmented based on drug type, application, infection, diagnosis test, route of administration, distribution channel, end-user, and region.

The segment stem cell transplantation accounted for approximately XX% of the cytomegalovirus infection treatment  market share

The stem cell transplantation segment is expected to hold the largest market share over the forecast period. In this segment, the development of government regulation, and rising funds for private manufacturers for stem cell treatment clinical trials would drive this market. 

In addition, people who similarly have immune reconstruction, and cell-mediated immunity testing for CMV are adding additional potential for developing stem cell transplantation in this market. For instance, in July 2021, a study publication in Springer states that the CMV infections are starting to surface, including Maribor and Adoptive T-cell treatment these are the innovative therapies for the CMV infections virus treatment.

 Furthermore, the rising number of new product approvals by the major players drives this market. In September 2022, Taked announced that Health Canada has authorized Livtencity drugs for the treatment of adults with post-transplant cytomegalovirus infections.

Geographical Analysis

North America accounted for approximately XX% of the cytomegalovirus infection treatment market share 

North America region is expected to hold the largest market share over the forecast period. The rising incidence of cytomegalovirus infections, and growing awareness among people, in this region, help to propel the market.

 As of March 2022, CMV is the most prevalent infectious cause of birth abnormalities in the United States, according to the Centers for Disease Control and Prevention (CDC). One baby out of every 200 is born with congenital CMV. In that one out of 5 babies have all symptoms and long-term severe health complications including hearing loss and also the majority of the people facing pregnancy loss due to CMV.

 Major players in this region's strategies such as R&D Clinical trials are expected to drive the market growth. For instance, in October 2021, Moderna announced the phase III trial of its CMV vaccine. Also in December 2021, the TIDS clinical trials group announced the launch of new clinical trials that affect the new CMV vaccines in adults.

 Moreover, industry key players' new product developments & approvals are driving the market growth in this region. For instance, Merck announced in June 2023 that the Prevymis medication has received FDA clearance in the United States for the prevention of CMV illness in adult kidney transplant recipients who are at high risk.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the cytomegalovirus infection treatment market. During the COVID-19 period, lack of development of novel CMV treatments, and more CMV patients were unable to get the required medicine effect in this market.

 In addition, industry key players in this market agreement during the pandemic period propelled the market. In September 2022, in the U.S. ProBioGen and the City of Hope used the AGE1.CR.Pix vaccine manufacturing for the CMV vaccine.

Market Segmentation

By Drug Type

• Cytovene
• Valcyte
• Foscarnet
•  Vistide
•  Others 

By Application

• Stem Cell Transplantation
• Organ Transplantation
• Congenital CMV infection
•  Others

By Infection

• Retinitis
• Pneumonia
• Esophagitis
• Colitis
• Others

By Diagnosis Test

• Serologic Test
• Polymerase Chain Reaction (PCR) Test
• Others

By Route of Administration

• Oral
• Intravenous

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
•  Online Pharmacy
• Others

By End-User

• Hospitals
• Specialty Clinics
• Homecare
• Others

By Region

• North America

• U.S.
• Canada
• Mexico

• Europe

• Germany
• U.K.
• France
• Spain
• Italy
• Rest of Europe

• South America

• Brazil
• Argentina
• Rest of South America

• Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

• Middle East and Africa

Competitive Landscape

The major global players in the cytomegalovirus infection treatment market include Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Fresenius Kabi Canada, GSK Plc, AiCuris Anti-infective Cures AG, Chimerix, Inc., Abbott, Bio-Rad Laboratories, Inc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd among others.

Key Developments

• On March 27, 2023, Mitsubishi Tanabe Pharma Corporation announced that MTPC received approval for an additional indication of the anti-cytomegalovirus agent Valixa Dry Syrup 5000mg (generic name: valganciclovir hydrochloride, hereinafter Valixa Dry Syrup) for the treatment of symptomatic congenital cytomegalovirus infection treatment
• On September 16, 2022, Takeda announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of maribavir for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).
• On June 8, 2022, Synklino completed a Series A raise of EUR 29.8 million to advance clinical trials of its drug candidate for the treatment of Cytomegalovirus (CMV). 

Why Purchase the Report?

• To visualize the cytomegalovirus infection treatment market segmentation based on drug type, application, infection, diagnosis test, route of administration, distribution channel end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of cytomegalovirus infection treatment market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.

The cytomegalovirus infection treatment market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies